Methods of in-vitro analysis using time-domain NMR spectroscopy

• US 7,940,045 B2
• Filed: 05/13/2009
• Issued: 05/10/2011
• Est. Priority Date: 01/14/2005
• Status: Active Grant

• Current Assignee: Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation)
• Original Assignee: Bayer Healthcare LLC (Bayer AG)
• Inventors: Benson, Thomas P., Carpenter, Scott E.
• Primary Examiner(s): Arana; Louis M
• Application Number:
  US12/465,287
• Publication Number:
  US 20090219022A1
• Time in Patent Office: 727 Days
• Field of Search: 324/321, 324/307
• US Class Current: 324/321
• CPC Class Codes: G01N 24/08 by using nuclear magnetic resonance G01N24/12 takes precedence
• CPC Class Codes: G01R 33/465 applied to biological material, e.g. in vitro testing

Abstract

An in vitro method of determining an analyte concentration of a sample includes placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer. The NMR spectrometer is tuned to measure a selected type of atom. A magnetic field is applied to the sample using a fixed, permanent magnet. At least one 90 degree radio-frequency pulse is applied to the sample. The radio-frequency pulse is generally perpendicular to the magnetic field. The 90 degree radio-frequency pulse is removed from the sample so as to produce a decaying NMR signal. The decaying NMR signal is measured at a plurality of times while applying a plurality of 180 degree refocusing radio-frequency pulses to the sample. The analyte concentration is calculated from the plurality of measurements associated with the decaying NMR signal and a selected model.

Claims

1. An in vitro method of determining an analyte concentration of a sample, the method comprising the acts of:

adding an NMR contrast agent to the sample to enhance detection of the analyte;

placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer, the NMR spectrometer being tuned to measure a selected type of atom;

applying a magnetic field to the sample;

applying at least one radio-frequency pulse to the sample;

removing the radio-frequency pulse from the sample so as to produce a decaying NMR signal;

measuring the decaying NMR signal; and

calculating the analyte concentration from the measurement associated with the decaying NMR signal and a selected model.

2. The method of claim 1, wherein the sample is a body fluid.

3. The method of claim 2, wherein the sample is a blood plasma sample.

4. The method of claim 2, wherein the sample is a blood serum sample.

5. The method of claim 2, wherein the sample is a urine sample.

6. The method of claim 1, wherein the method is a reagentless method.

7. The method of claim 1, wherein the model is a multivariate calibration model.

8. The method of claim 1, wherein the NMR spectrometer includes a permanent magnet less than about 1.4 tesla in the absence of hardware or electronics for locking or shimming.

9. An in vitro method of determining an analyte concentration of a sample, the method comprising the acts of:

placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer, the NMR spectrometer being tuned to measure a selected type of atom;

applying a magnetic field to the sample;

applying at least one radio-frequency pulse to the sample;

removing the radio-frequency pulse from the sample so as to produce a decaying NMR signal;

measuring the decaying NMR signal; and

calculating the analyte concentration from the measurement associated with the decaying NMR signal and a multivariate calibration model.

10. The method of claim 9, wherein the multivariate calibration model uses a chemometric technique.

11. The method of claim 10, wherein the chemometric technique uses partial least squares (PLS).

12. The method of claim 10, wherein the chemometric technique uses principal components regression (PCR).

13. The method of claim 10, further comprising fitting the decaying NMR signal to a polynomial function.

14. A method of determining an analyte concentration of a sample, the method comprising the acts of:

developing a multivariate calibration model by measuring NMR relaxation for a plurality of calibration samples;

measuring a NMR relaxation for a sample with a nuclear magnetic resonance (NMR) spectrometer;

comparing the measurement of the sample to the multivariate calibration model to identify the differences between the calibration model and the measurement of the test sample; and

calculating the analyte concentration from the comparison of the sample to the multivariate calibration model.

15. The method of claim 14, wherein the multivariate calibration model uses a chemometric technique.

16. The method of claim 15 wherein the chemometric technique uses at least one of partial least squares (PLS) and principal components regression (PCR).

17. The method of claim 15, wherein developing the multivariate model comprises:

selecting a set of training samples from the calibration samples;

developing a first model for the analyte with NMR relaxation measurements for the training samples;

selecting a set of test samples from the calibration samples not selected for the set of training samples; and

validating the first model by comparing NMR relaxation measurements of test samples to values predicted by the first model.

18. The method of claim 17, further comprising:

selecting a second set of training samples from the calibration samples;

developing a second model for the analyte with NMR relaxation measurements for the training samples of the second set of training samples;

selecting a second set of test samples from the calibration samples not selected for the second set of training samples; and

validating the second model by comparing NMR relaxation measurements of test samples of the second set of test samples to values predicted by the second model.

19. The method of claim 18, further comprising:

comparing the validation of the first model to the validation of the second model using a statistical test;

identifying a number of partial least squares (PLS) factors; and

developing a final calibration model using the NMR relaxation measurements for all of the calibration samples.

20. The method of claim 14, wherein the NMR spectrometer is a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer.